Anika Therapeutics: Advancing Orthopedic Regenerative Solutions
Anika Therapeutics specializes in hyaluronic acid (HA) technology, providing a portfolio of regenerative medicine and osteoarthritis pain management products. Based on official company data, the organization focuses on developing non-opioid treatments and tissue repair scaffolds designed to restore patient mobility and facilitate healing.
What are Anika’s core orthopedic technologies?
Anika’s product line centers on proprietary hyaluronic acid platforms applied to both joint pain and tissue regeneration. The company’s primary offerings include:
- OA Pain Management: This category features non-opioid HA injections, such as Cingal, which combines HA and a steroid into a single injection. Other products include Monovisc, a single-injection viscosupplement, and Orthovisc, a multi-injection treatment. According to the company, these therapies are designed to reduce stiffness, improve function, and provide pain relief.
- Regenerative Solutions: These products target tissue repair and bone health. The lineup includes Hyalofast, a scaffold for cartilage regeneration; Tactoset, an injectable bone substitute; NanoFx, a tool for bone marrow stimulation; and Integrity, which is used for rotator cuff and tendon repair augmentation.
How does the Integrity system support rotator cuff repair?
The Integrity system is designed to improve the biological environment and structural strength of rotator cuff repairs. Christopher E. Baker, MD, of the Florida Orthopaedic Institute, notes that the system enhances the strength and biological support of these repairs. According to Dr. Baker, patients using the system have shown positive outcomes, with postoperative imaging indicating a thickening of the repaired rotator cuff, allowing patients to return to daily activities without restrictions.
What is the clinical role of Cingal?
Cingal is positioned as a next-generation treatment for osteoarthritis pain, merging two approved therapies into one injection. By combining hyaluronic acid with a steroid, the treatment addresses both inflammation and pain. The company reports that this approach provides immediate pain relief that lasts for six months while simultaneously improving joint function and reducing stiffness.
Key Takeaways
- Focus on Non-Opioid Care: Anika’s injection-based therapies, including Cingal, Monovisc, and Orthovisc, provide alternatives to opioid-based pain management for osteoarthritis.
- Tissue Regeneration: Beyond pain management, the company utilizes its HA platform to create scaffolds and bone substitutes like Hyalofast and Tactoset to support the body’s innate healing processes.
- Clinical Application: Technologies like the Integrity system are actively used in orthopedic surgery to augment tendon and rotator cuff repairs, with clinical observations pointing to improved patient recovery and structural support.
As of June 2026, Anika continues to refine its hyaluronic acid technology platform, aiming to expand its reach in global orthopedic care by focusing on treatments that minimize the need for invasive procedures or long-term systemic pain medication.